Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects

被引:273
作者
Guzzo, CA
Furtek, CI
Porras, AG
Chen, C
Tipping, R
Clineschmidt, CM
Sciberras, DG
Hsieh, JYK
Lasseter, KC
机构
[1] Merck Res Labs, Blue Bell, PA USA
[2] Merck Res Labs, West Point, PA USA
[3] Merck Res Labs, Terlings Pk, England
[4] Clin Pharmacol Associates, Miami, FL USA
关键词
D O I
10.1177/009127002401382731
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Safety and pharmacokinetics (PK) of the antiparasitic drug ivermectin, administered in higher and/or more frequent doses than currently approved for human use, were evaluated in a double-blind, placebo-controlled, dose escalation study. Subjects (n = 68) were assigned to one of four panels (3:1, ivermectin/placebo): 30 or 60 mg (three times a week) or 90 or 120 mg (single dose). The 30 mg panel (range: 347-594 mug/kg) also received a single dose with food after a 1-week washout. Safety assessments addressed both known ivermectin CNS effects and general toxicity. The primary safety endpoint was mydriasis, accurately quantitated by pupillometry. Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA-approved dose of 200 mug/kg. All dose regimens had a mydriatic effect similar to placebo. Adverse experiences were similar between ivermectin and placebo and did not increase with dose. Following single doses of 30 to 120 mg, AUC and C-max were generally dose proportional, with t(max) similar to4 hours and t(1/2) similar to18 hours. The geometric mean AUC of 30 mg ivermectin was 2.6 times higher when administered with food. Geometric mean AUC ratios (day 7/day 1) were 1.24 and 1.40 for the 30 and 60 mg doses, respectively, indicating that the accumulation of ivermectin given every fourth day is minimal. This study demonstrated that ivermectin is generally well tolerated at these higher doses and more frequent regimens.
引用
收藏
页码:1122 / 1133
页数:12
相关论文
共 21 条
[1]   Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children [J].
Addiss, DG ;
Beach, MJ ;
Streit, TG ;
Lutwick, S ;
LeConte, FH ;
Lafontant, JG ;
Hightower, AW ;
Lammie, PJ .
LANCET, 1997, 350 (9076) :480-484
[2]   TOLERANCE OF SINGLE HIGH-DOSE IVERMECTIN FOR TREATMENT OF LYMPHATIC FILARIASIS [J].
ADDISS, DG ;
EBERHARD, ML ;
LAMMIE, PJ ;
HITCH, WL ;
SPENCER, HC .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1991, 85 (02) :265-266
[3]  
AWADZI K, 1994, TROP MED PARASITOL, V45, P203
[4]   Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus [J].
Baraka, OZ ;
Mahmoud, BM ;
Marschke, CK ;
Geary, TG ;
Homeida, MMA ;
Williams, JF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (05) :407-410
[5]   Treatment of Pediculus humanus var. Capitis infestation in Cowlitz County, Washington, with ivermectin and the LiceMeister® comb [J].
Bell, TA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (10) :923-924
[6]   MASS CHEMOPROPHYLAXIS OF LYMPHATIC FILARIASIS WITH A SINGLE DOSE OF IVERMECTIN IN A POLYNESIAN COMMUNITY WITH A HIGH WUCHERERIA-BANCROFTI INFECTION-RATE [J].
CARTEL, JL ;
NGUYEN, NL ;
MOULIAPELAT, JP ;
PLICHART, R ;
MARTIN, PMV ;
SPIEGEL, A .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (05) :537-540
[7]   Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin [J].
Cooper, PJ ;
Awadzi, K ;
Ottesen, EA ;
Remick, D ;
Nutman, TB .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (03) :738-742
[8]   A FIELD-STUDY OF THE EFFECTS OF IVERMECTIN ON ECTOPARASITES OF MAN [J].
DUNNE, CL ;
MALONE, CJ ;
WHITWORTH, JAG .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1991, 85 (04) :550-551
[9]   IVERMECTIN - A LONG-ACTING MICROFILARICIDAL AGENT [J].
ETTE, EI ;
THOMAS, WOA ;
ACHUMBA, JI .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1990, 24 (04) :426-433
[10]  
Fink D. W., 1989, Ivermectin and abamectin., P113